BFM
BTTX

Boothbay Fund Management’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Boothbay Fund Management’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-427,943
Closed -$4.25M – 2275
2021
Q2 		$4.25M Buy
+427,943
New +$4.25M 0.14% 164

Other funds holding BTTX

SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return
SV
Starboard Value New York $4.52B AUM 19.34% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Boothbay Fund Management's BTTX Position: Q3 2021 in Review

Boothbay Fund Management sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q3 2021, closing a stake of 427,943 shares — an estimated $4.25M sold.

Boothbay Fund Management first reported a position in BTTX in Q2 2021 and held it in 1 quarter. The position peaked at $4.25M in Q2 2021. 27 funds tracked by Wall St. Rank hold BTTX as of Q3 2021.

  • Boothbay Fund Management reported no remaining Better Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 427,943 Better Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $4.25M.
  • Boothbay Fund Management first reported a position in Better Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Boothbay Fund Management's Better Therapeutics, Inc. Common Stock position peaked at $4.25M in Q2 2021.
  • 27 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.